MCLENA-1: A Clinical Trial for the Assessment of Lenalidomide in Amnestic MCI Patients

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 22, 2020

Primary Completion Date

May 31, 2025

Study Completion Date

May 31, 2025

Conditions

Cognitive Impairment, MildCognitive DysfunctionAmyloid PlaqueNeurodegenerationInflammation, Brain

Interventions

DRUG

Lenalidomide 10 mg

Lenalid

DRUG

Placebo

Trial Locations (2)

St. Joseph's Hospital and Medical Center, Phoenix

Cleveland Clinic Lou Ruvo Center for Brain health, Las Vegas

All Listed Sponsors

collaborator

National Institute on Aging (NIA)

NIH

collaborator

The Cleveland Clinic

OTHER

lead

St. Joseph's Hospital and Medical Center, Phoenix

OTHER

NCT04032626 - MCLENA-1: A Clinical Trial for the Assessment of Lenalidomide in Amnestic MCI Patients | Biotech Hunter | Biotech Hunter